Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.00%
$3.88
0% positive prob.
5-Day Prediction
+0.00%
$3.88
0% positive prob.
20-Day Prediction
+0.00%
$3.88
0% positive prob.
SEC 8-K filings with transcript text
Oct 23, 2025 · 100% conf.
1D
+0.00%
$3.88
Act: -7.60%
5D
+0.00%
$3.88
Act: -28.09%
20D
+0.00%
$3.88
Act: -35.31%
false 0001933567
0001933567
2025-10-23 2025-10-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF
THE
Date of Report (Date of earliest event reported): October 23, 2025
Neuraxis, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-41775
45-5079684
(State or other jurisdiction
of incorporation)
(Commission
File Number)
Employer
Identification No.)
11611 N. Meridian St, Suite 330 Carmel, IN 46032
(Address of principal executive offices)
Registrant’s telephone number, including area code: (812) 689-0791
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
NYSE American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On October 23, 2025, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $4.4 million as of September 30, 2025. On a preliminary unaudited basis, the Company expects its net sales to be approximately $0.8 million, its gross profits to be approximately $0.7 million, and its operating loss to be approximately $2.1 million, for the three months ended September 30, 2025. On a preliminary unaudited basis, the Company expects its net sales for the nine months ended September 30, 2025 to be approximately $2.6 million as compared to approximately $1.9 million for the nine months ended September 30, 2024. As the Company completes its quarter-end financial statement close process and finalizes its financial statements and accompanying notes for the three and nine months ended September 30, 2025, the Company will be required to make significant judgments in a number of areas that may result in the estimates provided herein being different than the final reported amounts.
These preliminary estimates have been prepared by and are the responsibility of the Company’s management. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary estimates or the accounting treatment thereof and does not express an opinion or any other form of assurance with respect thereto. The Company expects to complete its financial statements for the three and nine months ended September 30, 2025 subsequent to the filing of this Item 2.02 8-K. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to these preliminary estimates and those changes could be material. Accordingly, undue reliance should not be placed on these preliminary estimates.
The information contained in Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 23, 2025
By: /s/ Brian Carrico
Name: Brian Carrico
Title: President and Chief Executive Officer
Jan 8, 2025
false 0001933567
0001933567
2025-01-08 2025-01-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF
THE
Date of Report (Date of earliest event reported): January 8, 2025
Neuraxis, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-41775
45-5079684
(State or other jurisdiction
of incorporation)
(Commission
File Number)
Employer
Identification No.)
11611 N. Meridian St, Suite 330
Carmel,
(Address of principal executive offices)
Registrant’s telephone number, including area code: (812) 689-0791
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On January 8, 2025, Neuraxis, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its preliminary unaudited information about the Company’s estimated revenues for the three and twelve months ended December 31, 2024. A copy of the Press Release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The preliminary financial information contained in the Press Release is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2024 or its results of operations as of such date. This preliminary financial information is subject to completion of the Company’s normal financial close procedures. These procedures and the audit of the Company’s financial statements for the year ended December 31, 2024 are ongoing and could result in changes to the preliminary financial information.
The information contained in Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Exhibits
99.1
Neuraxis, Inc. press release dated January 8, 2025, announcing Preliminary Unaudited Fourth Quarter 2024 Results.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2025
By:
/s/ Brian Carrico
Name:
Brian Carrico
Title:
President and Chief Executive Officer
Nov 12, 2024
false 0001933567
0001933567
2024-11-12 2024-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF
THE
Date of Report (Date of earliest event reported): November 12, 2024
Neuraxis, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-41775
45-5079684
(State or other jurisdiction
of incorporation)
(Commission
File Number)
Employer
Identification No.)
11611 N. Meridian St, Suite 330
Carmel,
(Address of principal executive offices)
Registrant’s telephone number, including area code: (812) 689-0791
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 12, 2024 Neuraxis, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information contained in Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Exhibits
99.1
Neuraxis, Inc. press release dated November 12, 2024, announcing third quarter 2024 financial results.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 12, 2024
By:
/s/ Brian Carrico
Name:
Brian Carrico
Title:
President and Chief Executive Officer
This page provides Neuraxis Inc. (NRXS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on NRXS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.